Video

Dr. Hafron explains the benefits of Jelmyto in UTUC since its approval

Author(s):

Urology Times staff
Conference|LUGPA Annual Meeting

"We're seeing that it's beneficial to the patient—it’s easier, they don't require a general anesthetic, and we don't have to bring him to the hospital," says Dr. Hafron.

During the 2022 LUGPA Annual Meeting, Jason Hafron, MD, sat down with Urology Times® to discuss how his use of Jelmyto has evolved since the low-grade upper tract urothelial carcinoma treatment was approved in April 2020. Dr. Hafron is the Chief Medical Officer and Director of Clinical Research at the Michigan Institute of Urology and a professor of urology at Oakland University.

Related Videos
Related Content
Investigational Combination Immunotherapy Treatment for High-Risk, Late-Stage Prostate Cancer Patients Available in Michigan
March 31st 2025

Investigational Combination Immunotherapy Treatment for High-Risk, Late-Stage Prostate Cancer Patients Available in Michigan

Michigan Institute of Urology
Michigan Institute of Urology is a clinical trial site for LEGION-100.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
February 18th 2025

RETAIN-2 interim data promising for dose-dense MVAC plus nivolumab in MIBC

Benjamin P. Saylor
“Among active surveillance patients, 82% are metastases-free, and 60% were metastases-free and had an intact, unradiated bladder,” said Pooja Ghatalia, MD.
blurred photo of a clinic hallway
May 28th 2023

2023 AUA highlights in benign urology

Urology Times staff
Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
Human kidney cross section on science background. 3d render. | Image Credit: © Rasi - stock.adobe.com
February 17th 2025

Casdatifan is linked with promising safety, efficacy in clear cell RCC

Benjamin P. Saylor
“Over 80% of patients…had at least 2 lines of therapy, so this is a heavily refractory population,” said Toni K. Choueiri, MD, FASCO.
Urinary bladder cancer | Image Credit: © Matthieu - stock.adobe.com
February 16th 2025

Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC

Benjamin P. Saylor
"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.
© 2025 MJH Life Sciences

All rights reserved.